Clinical trial
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and…
NCT00052611 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00052611 |
|---|---|
| Title | Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia |
| Official title | Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 23 |
| Start date | Jun 1, 2002 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: